3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
7
Fallopian Tube Neoplasms
6
Breast Neoplasms
6
Neoplasms
4
Sarcoma
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Multi-centric Castleman's Disease
2
Lymphoma, B-Cell
2
Sarcoma, Kaposi
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Primary Effusion
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Lymphadenopathy
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Invasive Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HIV Infections
1
Glioma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Interventions
Rituximab
25
Lenalidomide
20
Cyclophosphamide
18
obinutuzumab
8
Vincristine
8
Doxorubicin
8
Prednisone
7
Bendamustine Hydrochloride
7
tazemetostat
6
ibrutinib
6
Biopsy
6
venetoclax
5
pembrolizumab
5
fludarabine
5
Specimen Handling
5
CT-P10
5
fludarabine phosphate
4
R-CHOP protocol
4
Peripheral Blood Stem Cell Transplantation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Prednisolone
3
Etoposide
3
tocilizumab
2
copanlisib
2
axicabtagene ciloleucel
2
atezolizumab
2
acalabrutinib
2
abexinostat
2
Whole-Body Irradiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Follicular
×
liposomal doxorubicin
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled